Upgrading nirmatrelvir to inhibit SARS-CoV-2 Mpro via DeepFrag and free energy calculations

The first oral drug for the treatment of COVID-19, Paxlovid, has been authorized; however, nirmatrelvir, a major component of the drug, is reported to be associated with some side effects. Moreover, the appearance of many novel variants raises concerns about drug resistance, and designing new potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Nguyen Minh, Nguyen, Trung Hai, Pham, Minh Quan, Hong, Nam Dao, Tung, Nguyen Thanh, Vu, Van V., Quang, Duong Tuan, Ngo, Son Tung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233213/
https://www.ncbi.nlm.nih.gov/pubmed/37295158
http://dx.doi.org/10.1016/j.jmgm.2023.108535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233213/
https://www.ncbi.nlm.nih.gov/pubmed/37295158
http://dx.doi.org/10.1016/j.jmgm.2023.108535

Ejemplares similares